Melanoma

Quest’s New Predictive Gene Expression Test Aids Personalized Melanoma Treatment

The predictive gene expression test utilizes a combination of analysis of patient age and tumor thickness with advanced profiling technology.

Melanoma

CXCL 13 Protein Is Potential Biomarker Measuring Immunotherapy Response

When T cells are activated they release the CXCL13 protein, which helps attract more B cells and T cells to the tumor site.

Melanoma

Proscia’s AI Selected for Skin Pathology

Unilabs and Proscia have announced that the diagnostic group has chosen Proscia's DermAI skin pathology solution.

Multicancer Blood Test, Combined with Imaging, Shows Promise as Screen for Cancer

May 4, 2020 | Breast, Cancer, Cervical (HPV), Leukemia, Lung Cancer, Lymphoma, Melanoma, Molecular Diagnostics, Pancreatic, Prostate, Unknown Origin & Other Cancer Types

The blood test followed by PET-CT imaging was 99.6% specific for cancer.

Biocare Medical Launches Seven Antibody Markers for Clinical Diagnostic and Cancer Research Applications

Apr 27, 2020 | Biochemicals & Chemical Reagents, Cancer, Melanoma, Tissue Processing

The launch focuses on several immunooncology markers that are critical for early-stage cancer drug development and patient treatment.

Bio-Rad Introduces Anti-Ipilimumab Antibodies

Apr 27, 2020 | Biochemicals & Chemical Reagents, Cancer, Melanoma

The highly specific and high-affinity antibodies are suitable for bioanalytical and patient drug level monitoring assays for the immune checkpoint inhibitor ipilimumab.

Interventional Study to Evaluate Multicancer Early Detection Test

Apr 21, 2020 | Breast, Cancer, Cervical (HPV), Leukemia, Lung Cancer, Lymphoma, Melanoma, Molecular Diagnostics, Pancreatic, Prostate, Unknown Origin & Other Cancer Types

The Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.

Study Offers Promise for Multicancer Detection from a Single Blood Draw

Apr 6, 2020 | Breast, Cancer, Cervical (HPV), Leukemia, Lung Cancer, Lymphoma, Melanoma, Molecular Diagnostics, Pancreatic, Prostate, Unknown Origin & Other Cancer Types

Bluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.

Improved pH Probes May Aid in Monitoring Cancer

Feb 7, 2020 | Cancer, Melanoma

Nanopipettes with zwitterionic membranes may offer improved monitoring of changes in pH surrounding living cells, which can indicate traits of invasive cancer cells and their response to treatment.

Proscia Granted US Patent for AI-Powered Dermatopathology

Dec 19, 2019 | Melanoma, Slides, Software

The newly issued patent centers around the use of machine learning to classify skin biopsies.

New Liquid Biopsy Blood Test Improves Breast Cancer Diagnostics

Sep 9, 2019 | Breast, Melanoma, Specimen Collection & Handling

The TARDIS test could help avoid unnecessary surgeries and enable physicians to continuously monitor cancer.

Liquid Biopsies Guide Improved Cancer Treatment

Aug 26, 2019 | Breast, Cytology, Histology, Leukemia, Lung Cancer, Melanoma, Molecular Diagnostics, Prostate

Monitoring cancer therapy in real time enables physicians to make smarter treatment decisions.

Study Supports Tumor-Informed Blood Test as a Predictor of Cancer Survival

Jul 30, 2019 | Melanoma

Study results support use of the blood test as a surrogate endpoint in clinical trials to assess the effectiveness of immune checkpoint inhibitors.

January 2019 Product Spotlight: 2019 Emerging Technologies Showcase

Apr 14, 2019 | Breast, Cardiovascular, Culture Media, Lymphoma, Melanoma, Prostate, Slides

Nano-Signature Discovery Could Revolutionize Cancer Diagnosis A quick and easy test to...

Myriad’s MyPath Melanoma Test Gets Local Coverage Determination

Apr 2, 2019 | Melanoma

The test will help patients receive a definitive diagnosis for suspicious skin lesion biopsies.

Myriad Supports New Guidelines Recommending Genetic Testing for Those with Breast Cancer

Mar 20, 2019 | Breast, Melanoma

Study data demonstrate that about half of patients have clinically actionable mutations that are being missed.

Lymph Node Analysis Could Improve Melanoma Treatment Options

Mar 4, 2019 | Melanoma, Research

Studies are demonstrating the potential of the Parsortix system to enhance laboratory efficiency, reduce costs, support medical decisionmaking, and improve patient care.

Qiagen Expands NGS Portfolio with Oncology and Immunooncology Panels

Dec 20, 2018 | Melanoma, Prostate

The research panels can be performed using Qiagen’s GeneReader NGS system and other platforms, providing deep analysis of disease-related genomic mutations.

Category: Melanoma

Melanoma

Melanoma

Melanoma